Trials / Recruiting
RecruitingNCT05978466
MANAGE-AF Registry -MANAGEment of Atrial Fibrillation Outcomes Registry (MANAGE-AF)
MANAGEment of Atrial Fibrillation Outcomes Registry (MANAGE-AF)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- CorVita Science Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to learn more about the normal care of patients with a new or pre-existing diagnosis of atrial fibrillation (AF). These abnormal and irregular heartbeats place patients at increased risk of developing clots in their bloodstream that could potentially lead to stroke. Normal care is designed to help prevent this from happening and to lessen or eliminate the symptoms patients may have. There are many different types of AF as well as numerous ways in which a variety of patients are treated. The investigators are interested in gathering more information to better keep track of patient treatment patterns (trends) that may differ from physician to physician, hospital to hospital, medication to medication, patient to patient and if necessary, procedure to procedure.
Detailed description
The objective of this research is to establish a contemporary and simple to construct AF management registry that expands progressively over the continuum of care for each individual patient. The registry will be used to determine the course and progression of AF management in preventing thrombo-embolic events using rhythm and rate control interventions. Primary endpoints: 1. Atrial fibrillation natural history 2. Thrombo-embolic event 3. Death Secondary endpoints: 1. Bleeding 2. Pro-arrhythmia 3. Patient adherence 4. Treatment complication
Conditions
Timeline
- Start date
- 2017-12-22
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2023-08-07
- Last updated
- 2024-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05978466. Inclusion in this directory is not an endorsement.